ANVISA Drug Registration: Brazil Pharmaceutical Regulatory Requirements
Drug registration in Brazil is managed by ANVISA (Agencia Nacional de Vigilancia Sanitaria) under Law 6,360/1976 and implementing RDC (Resolucao da Diretoria Colegiada) regulations. Brazil classifies drugs into three categories: new drugs (novo), generics (generico), and similar drugs (similar). Registration generally requires a CTD-format dossier, a valid GMP certification (CBPF) where applicable, and separate CMED pricing steps before launch. Review timing varies by product type and ANVISA workload, so applicants should confirm current queue and priority status rather than rely on a fixed standard timeline.
Key Takeaways
Key Takeaways
- ANVISA classifies drugs into new, generic (generico), and similar (similar) categories, each with distinct registration requirements under RDC resolutions
- A Certificate of Good Manufacturing Practice (CBPF) from ANVISA is mandatory and requires GMP inspection of all manufacturing sites, including foreign facilities
- Drug pricing in Brazil is regulated by CMED (Camara de Regulacao do Mercado de Medicamentos), requiring price approval before commercial launch
- ANVISA uses CTD-format dossier processes, but applicants should verify the current petitioning workflow rather than assume full ICH eCTD gateway implementation
- ANVISA drug registration is the regulatory pathway for obtaining marketing authorization for pharmaceutical products in Brazil, the largest pharmaceutical market in Latin America. Brazil's regulatory framework has evolved substantially over the past two decades, but applicants should be careful not to overstate international-recognition claims without checking current WHO and ANVISA materials.
- Understanding ANVISA's requirements is essential for any pharmaceutical company seeking to access the Brazilian market. The registration process involves product-category-specific dossier requirements, mandatory GMP certification, regulated pricing, and Brazil-specific clinical data expectations.
- In this guide, you will learn:
- ANVISA's organizational structure and legal framework
- Drug categories in Brazil: new, generic, and similar
- Registration dossier requirements by category
- eCTD implementation status in Brazil
- GMP certification (CBPF) requirements
- Drug pricing regulation (CMED)
- Clinical trial requirements and ethics approval
- Registration renewal and post-market obligations
- ---
ANVISA: Organizational Structure and Legal Framework
What Is ANVISA?
ANVISA (Agencia Nacional de Vigilancia Sanitaria / National Health Surveillance Agency) is the Brazilian federal agency responsible for regulating and supervising products and services subject to health surveillance, including pharmaceuticals, biologics, medical devices, cosmetics, and food.
ANVISA was established in 1999 by Law 9,782 as an independent regulatory agency under the Ministry of Health. It operates with administrative independence and financial autonomy.
Key Regulatory Divisions
| Division | Function |
|---|---|
| GGMED (General Management of Medicines and Biological Products) | Drug registration assessment, including new drugs, generics, and similars |
| GGFIS (General Management of Inspection) | GMP inspections (domestic and international) |
| GGMON (General Management of Monitoring of Health Products) | Pharmacovigilance and post-market surveillance |
| GGTPS (General Management of Health Technology) | Health technology assessment support |
Legal Framework
| Law/Regulation | Subject |
|---|---|
| Law 6,360/1976 | Health surveillance of drugs, medicines, and other products |
| Law 9,787/1999 | Generic drugs law (Genericos) |
| Law 9,782/1999 | Creation of ANVISA |
| RDC 200/2017 (and successor RDCs) | Criteria for drug registration and post-registration changes |
| RDC 753/2022 | Updated drug registration requirements |
| RDC 73/2016 | Drug post-registration changes |
| RDC 55/2010 | Registration of biological products |
| RDC 24/2011 | GMP certification (CBPF) for international manufacturers |
The RDC (Resolucao da Diretoria Colegiada) is ANVISA's primary regulatory instrument. RDCs are binding resolutions issued by ANVISA's Collegiate Board of Directors and carry legal force.
Drug Categories in Brazil
Brazil classifies pharmaceutical products into three distinct categories, each with different registration requirements. This classification system is unique to Brazil and does not have a direct equivalent in FDA or EMA frameworks.
Category 1: New Drug (Medicamento Novo)
A new drug is a product containing a new active substance, a new combination, a new therapeutic indication, or a new pharmaceutical form not previously registered in Brazil.
| Characteristic | Details |
|---|---|
| Definition | Contains a new active substance or represents an innovation (new indication, new form, new combination) not previously registered |
| Data requirements | Full non-clinical and clinical dossier |
| Reference product | Not applicable (it is the innovator) |
| Regulatory basis | Law 6,360/1976, RDC 200/2017 (and successors) |
| Market exclusivity | Data protection provisions apply (see below) |
Category 2: Generic Drug (Medicamento Generico)
A generic drug is a product that is pharmaceutically equivalent to a reference drug (medicamento de referencia) and has demonstrated bioequivalence through appropriate studies.
| Characteristic | Details |
|---|---|
| Definition | Copy of a reference drug, demonstrating pharmaceutical equivalence and bioequivalence |
| Data requirements | CMC data + bioequivalence study (Module 3 + Module 5 BE) |
| Reference product | Must reference a registered "medicamento de referencia" |
| Naming | Must use the INN (Denominacao Comum Brasileira - DCB) only; cannot carry a brand name |
| Regulatory basis | Law 9,787/1999, RDC 200/2017 |
| Interchangeability | Generics are automatically interchangeable with the reference drug |
Category 3: Similar Drug (Medicamento Similar)
The similar drug category is a Brazil-specific classification that has no direct equivalent in the US or EU systems.
| Characteristic | Details |
|---|---|
| Definition | Contains the same active substance, concentration, dosage form, and route as a reference drug, but carries a brand name |
| Data requirements | CMC data + bioequivalence/relative bioavailability study (post-2003 requirements) |
| Reference product | Must reference a registered "medicamento de referencia" |
| Naming | Carries a brand name (unlike generics) |
| Regulatory basis | Law 6,360/1976, RDC 200/2017 |
| Interchangeability | Not automatically interchangeable; may be designated interchangeable by ANVISA after bioequivalence demonstration |
Historical context: Before 2003, similar drugs were registered without bioequivalence data. RDC 134/2003 (and subsequent updates) introduced bioequivalence requirements for similar drugs, requiring existing similar drugs to demonstrate bioequivalence by defined deadlines (the "adequacao" process). As of 2026, all similar drugs on the market should have bioequivalence data on file.
Reference Drug (Medicamento de Referencia)
The reference drug is the innovator product registered in Brazil, used as the comparator for generic and similar drug registrations. ANVISA publishes and maintains the "Lista de Medicamentos de Referencia" (List of Reference Drugs), which identifies the specific product to be used as the reference for each active substance.
Key rules:
- Only products designated by ANVISA as reference drugs can serve as comparators
- The reference drug must be registered and marketed in Brazil
- If no reference drug exists in Brazil, sponsors must petition ANVISA for designation or follow alternative pathways
Registration Dossier Requirements
Dossier Format
ANVISA has progressively adopted the ICH CTD format for drug registration dossiers, but the operational submission workflow is not the same as assuming a full ICH eCTD gateway model.
| Period | Dossier Format |
|---|---|
| Pre-2015 | ANVISA-specific format (paper and electronic PDF) |
| 2015-2020 | CTD format encouraged, paper still accepted |
| 2020-present | CTD-format processes expanded; ANVISA issued guidance on CTD-format petitioning |
| 2025 | ANVISA clarified that certain registration and post-registration petitions are submitted electronically first, with CTD documentation then filed by addendum |
Current status (2026): ANVISA expects CTD-format documentation for relevant petitions, but the agency's own 2025 guidance describes a petition-plus-addendum workflow rather than a blanket statement that all new-drug or biologic registrations are submitted through a standard ICH eCTD gateway. Sponsors should confirm the current operational process on the ANVISA portal before filing.
Module 1: Brazil-Specific Content
| Section | Content |
|---|---|
| Application form | ANVISA-specific petition form |
| Product labeling | Bula (package insert) in Portuguese per ANVISA template |
| Proof of registration abroad | If applicable, evidence of regulatory approval in other countries |
| GMP certificate | CBPF (Certificado de Boas Praticas de Fabricacao) for all manufacturing sites |
| Patent declaration | Declaration regarding patent status (relevant to generic/similar timing) |
| Pricing documentation | CMED pricing submission (separate process but required for market launch) |
Module 2: CTD Summaries
Standard ICH format. Module 2 summaries must be provided in Portuguese for new drug registrations. ANVISA may accept English-language Modules 3-5 with Portuguese summaries in Module 2.
Module 3: Quality (CMC)
Module 3 follows ICH M4Q. Key Brazil-specific considerations:
- Stability data: ANVISA requires stability studies conducted under Climatic Zone IVb conditions (30 degrees C / 75% RH long-term, 40 degrees C / 75% RH accelerated) per RDC 318/2019. This differs from ICH Zone II (25 degrees C / 60% RH). Sponsors must generate or provide Zone IVb data for Brazil.
- Drug substance specifications: Must comply with the Brazilian Pharmacopoeia (Farmacopeia Brasileira) where applicable monographs exist
- Excipients: Must be listed in the ANVISA-approved excipient list or individually justified
- Brazilian Pharmacopoeia: The 6th Edition (2019) is the current official pharmacopoeia. Where Brazilian Pharmacopoeia monographs exist, compliance is mandatory.
Module 4: Non-clinical
Required for new drug registrations. Not typically required for generic or similar drugs. Standard ICH M4S format.
Module 5: Clinical
For new drugs: Full clinical data package including pivotal efficacy and safety studies. ANVISA may request Brazil-specific clinical data if the treatment population or disease presentation differs significantly in Brazil.
For generic and similar drugs: Bioequivalence study reports. BE studies must comply with RDC 67/2014 (bioequivalence study guidance) and be conducted at ANVISA-certified bioequivalence centers.
GMP Certification: CBPF
What Is the CBPF?
The CBPF (Certificado de Boas Praticas de Fabricacao / Certificate of Good Manufacturing Practices) is ANVISA's GMP certificate. It is a mandatory prerequisite for drug registration in Brazil. No drug registration can be granted without a valid CBPF for each manufacturing site involved in the production of the drug substance and drug product.
CBPF for International Manufacturers
| Parameter | Details |
|---|---|
| Regulatory basis | RDC 24/2011 (and updates) |
| Scope | All foreign manufacturing sites that produce the drug substance or drug product for the Brazilian market |
| Inspection | ANVISA inspectors travel to the foreign site for on-site GMP inspection |
| Standards | WHO GMP standards and ANVISA-specific requirements |
| Validity | 2 years from issuance (requires renewal) |
| Cost | Inspection fees + travel/accommodation costs for ANVISA inspectors (borne by the applicant) |
| Timeline | 6-18 months from application to CBPF issuance (depending on ANVISA inspection schedule) |
CBPF Application Process
- Application submission: Submit CBPF application to ANVISA via the electronic system, including site master file and product information
- Document review: ANVISA reviews documentation for completeness
- Inspection scheduling: ANVISA schedules the on-site inspection (timing depends on ANVISA's inspection calendar and prioritization)
- On-site inspection: ANVISA inspectors conduct the GMP inspection at the foreign site. Inspections typically last 3-5 days.
- Inspection report: Inspectors prepare a report with findings
- CAPA submission: If deficiencies are identified, the manufacturer must submit a Corrective Action and Preventive Action (CAPA) plan
- CBPF issuance: Upon satisfactory resolution, ANVISA issues the CBPF
Inspection Scheduling Challenges
ANVISA's international inspection capacity has historically been a bottleneck. The agency inspects hundreds of foreign manufacturing sites, and scheduling can take 6-12 months from application. Sponsors should apply for CBPF well in advance of the planned registration filing.
Mutual recognition: ANVISA has entered into information-sharing and cooperation agreements with several regulatory authorities (FDA, EMA, Health Canada) but does not currently maintain full MRA-based GMP reliance. ANVISA may consider inspection reports from other authorities but retains the right to conduct its own inspections.
Clinical Trial Requirements in Brazil
Regulatory Framework for Clinical Trials
Clinical trials in Brazil are regulated by ANVISA and the ethics committee system (CEP/CONEP).
| Authority | Role |
|---|---|
| ANVISA | Regulatory authorization (clinical trial application) |
| CEP (Comite de Etica em Pesquisa) | Local/institutional ethics committee approval |
| CONEP (Comissao Nacional de Etica em Pesquisa) | National ethics commission; reviews trials involving specific categories (biologics, genetics, indigenous populations, etc.) |
Clinical Trial Application Process
- Ethics submission: Submit protocol to CEP at each participating institution. If the trial involves specific categories, CONEP review is also required.
- ANVISA submission: Submit clinical trial dossier to ANVISA (Dossiê de Desenvolvimento Clinico de Medicamento - DDCM)
- ANVISA review: ANVISA reviews within 90 days (180 days for Phase I trials involving new molecules)
- Dual approval required: Both ANVISA authorization and CEP/CONEP approval must be obtained before the trial can begin
Brazil-Specific Clinical Trial Requirements
- Informed consent: Must be in Portuguese, must comply with Resolution CNS 466/2012
- Post-trial access: Brazilian regulations require sponsors to provide post-trial access to the investigational product for subjects who benefited from treatment during the trial. This requirement has been a significant consideration for sponsors deciding whether to include Brazilian sites in global trials.
- Insurance: Sponsors must provide insurance coverage for clinical trial participants
- Brazilian investigator: At least one Brazilian investigator must be listed on the trial
- Product import: Investigational products must be imported through authorized channels with ANVISA approval
Drug Pricing: CMED
What Is CMED?
CMED (Camara de Regulacao do Mercado de Medicamentos / Chamber for Regulation of the Medicines Market) is the inter-ministerial body responsible for drug pricing regulation in Brazil. CMED sets maximum prices for pharmaceutical products, and no drug can be marketed in Brazil above the CMED-established price.
Pricing Process
| Step | Description |
|---|---|
| 1. Price submission | Sponsor submits pricing information to CMED, including international reference pricing data |
| 2. Price assessment | CMED evaluates the proposed price using its pricing methodology |
| 3. Price approval | CMED establishes the maximum factory price (PMF - Preco Maximo ao Fabricante) and maximum consumer price (PMC - Preco Maximo ao Consumidor) |
| 4. Annual adjustment | CMED adjusts prices annually based on an index that includes inflation, productivity factors, and inter-industry price adjustments |
Pricing Methodology
CMED's pricing methodology considers:
- International reference pricing: Prices in reference countries (Australia, Canada, Spain, France, Greece, Italy, New Zealand, Portugal, US)
- Therapeutic category: CMED classifies products by therapeutic category and assesses whether the new product offers therapeutic advantage over existing options
- Cost of treatment: Assessment of daily treatment costs relative to comparators
- Generic entry: When generics enter the market, reference drug prices may be reduced (mandatory discounts apply)
ICMS Tax Considerations
Drug prices in Brazil are affected by ICMS (Imposto sobre Circulacao de Mercadorias e Servicos), a state-level value-added tax. ICMS rates vary by state and by product category. The PMC (consumer price) established by CMED includes ICMS at specified rates. Different states may apply different effective consumer prices due to ICMS variations.
Data Protection in Brazil
Brazil provides data protection for new drugs through ANVISA's implementing regulations:
- Data protection period: 5 years from the date of registration in Brazil for new chemical entities
- Scope: During the data protection period, ANVISA will not accept registration applications for generic or similar drugs that rely on the innovator's data
- Limitations: Data protection does not prevent generic/similar registration based on independently generated data
Brazil's data protection period is shorter than the US (5 years for NCEs under Hatch-Waxman), EU (8+2+1 years), and Canada (8 years).
Patent Linkage
Brazil has a patent linkage mechanism that connects drug registration with patent status:
- ANVISA publishes submitted generic/similar drug applications for products with active patents
- Patent holders may oppose the registration if they believe it infringes their patents
- ANVISA's role is administrative (publication of applications); patent disputes are resolved through the courts
- The mechanism was reformed by Law 14,195/2021, which clarified ANVISA's limited role in patent matters
Registration Timeline and Process
Standard Timeline
| Phase | Duration (typical) |
|---|---|
| Pre-registration (CBPF + BE studies) | 6-18 months |
| Dossier preparation | 3-6 months |
| ANVISA screening | 1-2 months |
| ANVISA assessment | 12-18 months |
| Questions/response cycles | 3-6 months (if needed) |
| CMED pricing | 2-4 months (after registration) |
| Total (registration to market) | 18-36 months |
Registration Validity and Renewal
- Drug registrations in Brazil are valid for 5 years from the date of registration
- Sponsors must apply for renewal (renovacao) before expiration
- Renewal requires demonstration of continued compliance with registration conditions, updated stability data, and pharmacovigilance reports
- If renewal is not sought, the registration lapses and the product can no longer be sold in Brazil
Post-Registration Changes
Post-registration changes are governed by RDC 73/2016 (and subsequent updates). Changes are classified by risk level:
| Change Category | Description | ANVISA Action |
|---|---|---|
| Minor (Notificacao) | Low-risk changes (e.g., minor labeling changes) | Notification only; no prior approval required |
| Moderate (Prior notification) | Moderate-risk changes (e.g., minor specification changes) | Prior notification; may implement before ANVISA review |
| Major (Prior approval) | High-risk changes (e.g., new manufacturing site, significant process changes) | Prior ANVISA approval required before implementation |
International Convergence
ANVISA has increasingly aligned aspects of its medicines framework with international standards, including CTD-based dossier organization and ICH-related workstreams. But sponsors should distinguish between technical convergence, WHO benchmarking, and any specific reliance or recognition consequence, each of which has its own legal basis and source.
Biologics Registration (RDC 55/2010)
Biologic products follow specific registration requirements under RDC 55/2010 (and subsequent updates):
Registration Routes for Biologics
| Route | Applicable Products | Requirements |
|---|---|---|
| Individual development (novo) | Novel biologics | Full quality, non-clinical, and clinical dossier |
| Comparability pathway (biossimilar) | Biosimilars | Comprehensive comparability exercise (quality, non-clinical, clinical) vs. reference biologic |
Brazil-Specific Biologic Requirements
- Reference biologic: Must be registered in Brazil
- Comparability exercise: Follows ANVISA's biosimilar guidance, which is broadly aligned with WHO guidelines on evaluation of biosimilar biotherapeutic products
- Clinical comparability: Clinical studies (PK/PD and, in most cases, efficacy/safety) are required for biosimilar registration
- Immunogenicity: Comparative immunogenicity assessment is required
Submit the relevant registration petition to ANVISA and follow the current CTD-format dossier workflow described by the agency, along with any required CBPF documentation for manufacturing sites. The dossier requirements depend on the product category (new drug, generic, or similar). After registration, complete the separate pricing process with CMED before commercial launch.
Key Regulatory References
- Law 6,360/1976 (Health surveillance of drugs and medicines)
- Law 9,787/1999 (Generic drugs)
- Law 9,782/1999 (Creation of ANVISA)
- RDC 200/2017 (Drug registration criteria) and successor RDC 753/2022
- RDC 73/2016 (Post-registration changes)
- RDC 55/2010 (Biologic product registration)
- RDC 318/2019 (Stability studies)
- RDC 67/2014 (Bioequivalence studies)
- RDC 24/2011 (International GMP certification)
- Resolution CNS 466/2012 (Clinical trial ethics)
- Brazilian Pharmacopoeia, 6th Edition (2019)
- CMED Resolution 2/2004 (Pricing criteria) and updates
This guide reflects ANVISA regulatory requirements as of early 2026. Brazilian pharmaceutical regulations are actively evolving, particularly regarding eCTD implementation and international harmonization. Always verify current requirements on the ANVISA website (www.gov.br/anvisa) before filing.